Junning Cao

机构：Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center · ORCID：0000-0002-3146-9413

发表论文 228 篇 · 总被引 2054 次 · h-index 24

代表论文

• Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (2025 · Nature Cancer · 被引 51)
• Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 20)
• Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults (2025 · Blood Advances · 被引 5)
• Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial (2025 · Blood Cancer Journal · 被引 4)
• Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study (2025 · EClinicalMedicine · 被引 3)
• Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial (2025 · Clinical Drug Investigation · 被引 2)